• English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
On July 8th, China Biopharmaceutical (01177.HK) announced a further deepening of its strategic cooperation with GlaxoSmithKline (GSK.N). Under the expanded cooperation agreement, Chia Tai Tianqing Pharmaceutical Group, a subsidiary of China Biopharmaceutical, will be fully responsible for the import, distribution, hospital access, and promotion of two innovative respiratory drugs in mainland China: Flutemetixyl Inhalation Powder (Tronex) and Umemetidine-Vilanterol Inhalation Powder (Olex). Previously, the two companies had already reached a cooperation agreement on the localization of innovative drugs in the field of liver disease.Bernstein: Lowered its price target for Netflix (NFLX.O) from $110 to $100.Citigroup raised its price target for Johnson & Johnson (JNJ.N) from $285 to $298.Broadcom (AVGO.O) recovered some of its losses in pre-market trading and is currently down 0.5%. The company has reached an agreement with Apple (AAPL.O) to produce more than 15 billion chips.On July 8, Xi Jinping attended the National Science and Technology Awards Conference, the General Assembly of the Chinese Academy of Sciences and the Chinese Academy of Engineering, and the 11th National Congress of the China Association for Science and Technology, and delivered an important speech. Xi Jinping emphasized the need to promote the deep integration of scientific and technological innovation and industrial innovation, and to open up channels for the accelerated transformation of science and technology into real productive forces. Scientific and technological innovation should be application-oriented, while industrial innovation should focus on raising scientific questions. He stressed strengthening the national technology transfer system, creating diversified application scenarios and high-level industrial clusters, and promoting the application and iterative upgrading of independently developed technologies and products. He also called for improving the intellectual property protection system and building a science and technology finance system adapted to scientific and technological innovation.

Forecast for Gold Price: XAU/USD consolidates above $2,000 as investors await initial US S&P PMI data

Daniel Rogers

Apr 21, 2023 13:52

 272.png

 

During the Asian session, the price of gold (XAU / USD) is oscillating above the psychological resistance of $2,000.00. After a gradual increase, the price of gold has leveled off near $2,005.00 as investors await the release of preliminary S&P PMI data for the United States.

 

S&P500 futures have added some gains during the Asian session following three consecutive declines. As a result of Elon Musk's price-cutting frenzy, Tesla's revenue projections were gloomy, which dampened market sentiment. Near 101.77, the US Dollar Index (DXY) has extended its correction. The USD Index has been consolidating in a range between 100.90 and 102.03 for the past several trading sessions. Therefore, a move that exceeds the previously specified limit will be considered decisive.

 

The subdued USD index weighs on US Treasury yields as well. The demand for U.S. government bonds has increased as weekly unemployment claims have increased. The number of individuals claiming unemployment benefits rose to 245K, exceeding the consensus estimate of 240K. This indicated a softening in the labor market and bolstered expectations that the Federal Reserve (Fed) will not raise interest rates after the monetary policy meeting in May.

 

In the future, the publication of the preliminary US S&P PMI data will determine the impact of the Fed's rate hikes on the scope of economic activity. According to projections, the Manufacturing PMI and Services PMI will decline to 49.0 and 51.5, respectively. A preliminary PMI reading that is weaker than anticipated could impact heavily on the U.S. dollar.